BioLine RX Ltd (BLRX) FinancialsBLRXBioLine RX Ltd

Evaluating the bottom line, BioLine RX Ltd maintains a gross margin of 53.40%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1215.31%, while the net margin is -1450.94%. These profitability ratios, combined with a Return on Equity (ROE) of -48.36%, provide a clear picture of how effectively BLRX converts its operational activities into shareholder value.

In the context of the broader market, BLRX competes directly with industry leaders such as ALGS and AARD. With a market capitalization of $8.62M, it holds a significant position in the sector. When comparing efficiency, BLRX's gross margin of 53.40% stands against ALGS's 100.00% and AARD's N/A. Such benchmarking helps identify whether BioLine RX Ltd is trading at a premium or discount relative to its financial performance.

The company has shown inconsistent revenue growth, with Q2 2026 revenue at $0.3 million, unchanged from Q2 2025, and a gross margin of 53.40% in Q2 2026, which is significantly lower than previous quarters. Additionally, the forward P/E ratio is extremely high at 93.46, indicating that the stock may be overvalued given its current financial performance.